The European Patent Office (EPO) has published patent application EP4520394A2, detailing new therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases. The application was filed by Boehringer Ingelheim International GmbH and includes specific International Patent Classification (IPC) codes related to pharmaceutical compositions and their therapeutic applications. This publication represents the granting of a patent for these novel treatment approaches.

This is a patent publication, not a regulatory rule or guidance. Therefore, it does not impose direct compliance obligations on regulated entities. However, it signifies intellectual property protection for Boehringer Ingelheim's innovations in treating fibrosing lung diseases. Companies operating in the pharmaceutical sector, particularly those involved in respiratory therapeutics, should be aware of this patent as it may affect their research, development, and commercialization strategies in this therapeutic area.